Understanding HIV Single-Tablet Regimens (STRs)
HIV treatment has transformed dramatically over the past decade. What once required multiple pills taken at different times of day has been simplified into single-tablet regimens — a single pill taken once daily that contains a complete HIV treatment combination. For patients living with HIV, these STRs offer convenience, better adherence, and improved quality of life.
Indian pharmaceutical manufacturers have made these life-saving medications accessible and affordable. At 984 Online Pharmacy, patients can access high-quality Indian generic HIV STRs at a fraction of the cost of brand-name alternatives in Western markets.
TAF-Based vs TDF-Based Regimens: What’s the Difference?
Most modern HIV STRs are built around one of two nucleotide backbone options: Tenofovir Alafenamide (TAF) or Tenofovir Disoproxil Fumarate (TDF). Understanding the difference is key to choosing the right regimen.
- TAF (Tenofovir Alafenamide): Newer formulation, achieves higher drug levels inside cells with lower blood levels. Smaller doses (25mg vs 300mg), fewer kidney-related side effects, and less impact on bone density. TAF-based STRs include Kocitaf, Spegra, and Taficita.
- TDF (Tenofovir Disoproxil Fumarate): The original tenofovir formulation, well-studied and highly effective. Requires higher doses (300mg). Slightly higher risk of kidney and bone effects but a proven track record. TDF-based STRs include Acriptega, Viropil, and Tenvir-EM.
Top Indian Generic HIV Single-Tablet Regimens Compared
1. Kocitaf (Mylan) — TAF/FTC Backbone
Kocitaf contains Tenofovir Alafenamide (25mg) + Emtricitabine (200mg) from Mylan. This TAF-based backbone can be combined with Dolutegravir or other third agents. Kocitaf offers superior kidney safety compared to TDF-based options, making it ideal for long-term use. Available at $26-$29 for 30 tablets.
2. Spegra (Emcure) — Dolutegravir + TAF/FTC
Spegra combines Dolutegravir (50mg) + Tenofovir Alafenamide (25mg) + Emtricitabine (200mg) in a single pill. This is one of the most popular complete regimens globally, offering the gold-standard integrase inhibitor Dolutegravir with the safer TAF backbone. Priced at approximately $26-$29 for 30 tablets, Spegra represents excellent value compared to branded alternatives.
3. Taficita (Mylan) — TAF/FTC Backbone
Taficita contains Tenofovir Alafenamide (25mg) + Emtricitabine (200mg) from Mylan. This TAF/FTC backbone can be used with a third agent like Dolutegravir or Efavirenz. Available at $23-$29 for 30 tablets.
4. Tafero EM (Hetero) — TAF/FTC/EFV
Tafero EM combines Tenofovir Alafenamide (25mg) + Emtricitabine (200mg) + Efavirenz (600mg) from Hetero. This complete regimen includes Efavirenz, an NNRTI, forming a full HIV treatment in one pill. At $24-$29 for 30 tablets, it is one of the most affordable TAF-based complete regimens.
5. Acriptega (Mylan) — Dolutegravir + TDF/FTC
Acriptega combines Dolutegravir (50mg) + Tenofovir Disoproxil Fumarate (300mg) + Emtricitabine (200mg) from Mylan. While TDF-based, it remains highly effective and cost-efficient at $18-$22 for 30 tablets. Suitable for patients with healthy kidney function.
6. Tenvir-EM (Cipla) — TDF/FTC Backbone
Tenvir-EM from Cipla contains Tenofovir Disoproxil Fumarate (300mg) + Emtricitabine (200mg). This well-established TDF-based backbone is widely prescribed globally. Available at $20-$25 for 30 tablets.
7. Viropil (Emcure) — Dolutegravir + TDF/FTC
Viropil contains Dolutegravir (50mg) + Tenofovir Disoproxil Fumarate (300mg) + Emtricitabine (200mg) from Emcure. Available in 30-tablet and 90-tablet packs. This complete regimen offers excellent value for patients who tolerate TDF well.
Cost Comparison: Indian Generic vs Brand-Name HIV Medications
The cost difference between Indian generic HIV medications and brand-name counterparts in Western markets is dramatic:
- Indian generic STRs (Spegra, Acriptega, Tafero EM): $18-$29 per month
- Brand-name Biktarvy (USA): Approximately $3,500-$4,000 per month
- Brand-name Triumeq (USA): Approximately $2,800-$3,200 per month
- Brand-name Genvoya (USA): Approximately $3,000-$3,500 per month
Patients can save 90-99% by choosing Indian generic HIV medications from 984 Online Pharmacy. All products are sourced from WHO-GMP certified Indian manufacturers.
Important Considerations When Choosing an HIV Regimen
- Viral load and CD4 count: Your doctor prescribes based on your specific lab results
- Resistance profile: Previous treatment affects which medications will work
- Kidney function: TAF-based regimens are safer for patients with kidney concerns
- Drug interactions: Certain HIV medications interact with other drugs
- Cost: All options at 984 Online Pharmacy are significantly more affordable than brand names
Frequently Asked Questions
Can I switch from TDF to TAF? Yes. Many patients switch to TAF-based regimens for improved kidney and bone safety. Consult your doctor.
Are Indian generic HIV medications FDA approved? Many Indian generics are WHO-prequalified. Manufacturing facilities meet international GMP standards.
Do I need a prescription? Yes. Prescription medications require a valid prescription from a licensed healthcare provider.
How long does shipping take? International shipping typically takes 10-21 business days.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any HIV treatment regimen. Prices are approximate ranges and subject to change.
HIV single-tablet regimens (STRs) have revolutionized antiretroviral therapy by combining multiple active drugs into a single daily pill, dramatically improving adherence and quality of life for people living with HIV. The transition from multi-pill regimens to STRs was identified by the World Health Organization as one of the most significant advances in HIV care, with studies showing that STRs improve adherence rates by 15-25% compared to multi-tablet regimens, leading to higher rates of viral suppression and reduced risk of drug resistance. Indian generic manufacturers have been instrumental in making STRs accessible at a fraction of the cost of brand-name equivalents.
The choice between TAF-based (tenofovir alafenamide) and TDF-based (tenofovir disoproxil fumarate) regimens is an important clinical consideration. TAF achieves higher intracellular concentrations of the active metabolite with lower plasma levels, resulting in significantly less renal toxicity and bone mineral density loss compared to TDF. However, TAF is associated with slightly higher lipid levels and may not be suitable for patients with severe renal impairment (eGFR below 30 mL/min). For patients with established osteoporosis or chronic kidney disease, TAF-based regimens such as Kocitaf or Spegra are strongly preferred. For younger patients with normal renal function and bone density, TDF-based options such as Tenvir-EM remain effective and are the most affordable choices, costing $10-25 per month compared to TAF-based regimens at $18-35 per month.
Dolutegravir, the integrase strand transfer inhibitor (INSTI) included in Spegra and several other STRs, has become the preferred third agent in most modern HIV regimens due to its high genetic barrier to resistance, excellent tolerability profile, and minimal drug interactions. The ADVANCE and NAMSAL trials demonstrated that dolutegravir-based regimens were non-inferior to efavirenz-based regimens with better tolerability and fewer discontinuations due to adverse effects. However, dolutegravir is associated with a small increased risk of neural tube defects when taken at the time of conception, leading to a warning for women of childbearing potential. Patients of reproductive age should discuss contraception options with their healthcare provider when initiating dolutegravir-containing regimens. Despite this consideration, dolutegravir remains the WHO-recommended first-line and second-line INSTI for most adults and adolescents living with HIV.